Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uridine monophosphate (UMP) is a pyrimidine nucleotide composed of the nucleobase uracil, the sugar ribose, and one phosphate group. It is a fundamental building block of RNA and plays a central role in cellular metabolism as both an intermediate in pyrimidine biosynthesis and as a precursor for other nucleotides. In humans, it is synthesized from orotidylate via decarboxylation by UMP synthase. As a supplement, UMP has been studied for its potential to enhance cognitive function, increase synapse density, support neurotransmitter synthesis (notably acetylcholine and dopamine), improve mood, reduce nerve pain when combined with B vitamins, protect mitochondria and heart function, reduce inflammation, and support brain health. It easily crosses the blood-brain barrier when taken orally[1][2][6][7][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on uridine monophosphate.